#For clinicians

Written for prescribing clinicians, with full citation chains.

A 218,043-person retrospective cohort linked GLP-1 use with lower cardiovascular event and death risks in serious mental illness.

A Saudi pharmacy-student survey found a mean GLP-1 safety knowledge score of 7.6 out of 17, with a 26.5% response rate.

An editorial highlights a matched cohort linking prior GLP-1 or tirzepatide use with fewer early cardiorenal events after surgery.

SLIM LIVER found improved liver-fat and blood-marker results with semaglutide in people with HIV, but the trial had no control group.

Seven randomized trials suggest GLP-1 drugs, including semaglutide, can reduce antipsychotic-associated metabolic harm.

A retrospective cohort linked higher-dose oral semaglutide and SGLT-2 inhibitor use with improved arterial stiffness, without proving causation.

FLOW established kidney-outcome evidence for semaglutide in diabetic CKD. A translational review explains why SGLT2 combination trials are next.

A Canadian analysis estimated how far GLP-1 receptor agonist prices would need to fall to become cost-effective.

A Lancet letter raises the maintenance question. SURMOUNT-MAINTAIN supports continued tirzepatide but does not supply an individual dosing formula.

One patient taking tirzepatide completed 17 ECT sessions without complications, but the case report cannot establish a safe protocol.

A letter on tirzepatide ocular outcomes has no public abstract. The underlying cohort found associations, not proof of eye protection.

A matched MASLD cohort linked tirzepatide to fewer deaths and liver events than SGLT2 inhibitors, but it cannot prove superiority.